DesignGroup worked with OhioHealth to design space for the new Blood and Marrow Transplant Program at OhioHealth Riverside Methodist Hospital and OhioHealth Arthur G.H. Bing, MD, Cancer Center, which has energized OhioHealth’s presence in Central Ohio for cancer patients. The project involved three different components: an outpatient clinic and infusion center, an inpatient unit and a cell processing lab.
THE INPATIENT UNIT
The new BMT Inpatient Unit consists of 22 patient rooms, eight medical oncology rooms, one isolation ADA patient room and one AII/PE ADA patient room. Three centrally located staff stations provide support across multiple inpatient programs. A typical stay for these highly immune-compromised patients can range from 30-90 days at a time during their treatment. The unit embraces a clean and sophisticated aesthetic, creating a calming and warm environment. Patient rooms feature a neutral palette with soft accents and a warm wood element. Upgraded patient board technology facilitates real-time communication and connection among patients, families, and providers.
The elevator lobby sets the tone with water-inspired tile, complemented by soothing dark blue accents and artwork. The family lounge offers comforts of home with a kitchenette, laundry room, consult space, and family toilet, providing respite for patients and their families.
OUTPATIENT CLINIC + INFUSION CENTER
The Bing Conferencing Center underwent a complete renovation to house the new BMT Outpatient Clinic and BMT Oncology Infusion. The infusion center features 15 private infusion spaces, two large private infusion rooms, and an apheresis room with two collection bays. The clinic includes 10 exam rooms designed with flexible and space-saving metrics, along with a procedure room for class II biopsy procedures. Additionally, the clinic incorporates expansion space at the back for future growth.
CELL PROCESSING LAB
The final component is the new OhioHealth Cell Processing Lab, which is an integral part of the HSC (Hematopoietic Stem Cell) transplant program. It’s goal is to include chimeric antigen receptor (CAR) T-Cell therapy, which extracts immune cells from a patient’s blood and alters them to be reintroduced back into the patient to attack cancer cells. The lab is also capable of cryopreserving stem cells for long term storage.